Vyant Bio Inc

VYNT | $0.194 -8.51% 19K

(0.0% 1d) (0.0% 1m) (-69.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1671.02% volume)
Earnings Calendar: 2023-03-29
Market Cap: $ 1,227,778
https://www.vyantbio.com
Sec Filling | Patents | n/a employees

(US) Vyant Bio operates two wholly-owned subsidiaries, StemoniX and vivoPharm. The Company will immediately begin to execute on the integration of these two leading businesses, to converge human-powered scientific and technology-based systems and expertise with years of preclinical experience to de-risk and accelerate discovery and development of preclinical and clinical pipelines for biopharma partners as well as for the proprietary pipeline of the Company.

add to watch list Paper trade email alert is off

Viridian Therapeutics Inc

VRDN | $15.64 -1.57% -1.47% 880K

Health Care and Social Assistan...

(0.0% 1d) (-9.8% 1m) (-41.6% 1y) (0.0% 2d) (0.0% 3d) (-2.9% 7d) (13.93% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 981,684,795
http://www.miragen.com/
Sec Filling | Patents | 27 employees

(US) Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED). Viridian is headquartered in Boulder, Colorado , with research and development operations in Waltham, Massachusetts.

treatment antibody

add to watch list Paper trade email alert is off